Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option and license agreement with Taiho Pharmaceutical Co. Ltd., for the potential development and commercialization of product candidates in Arcus s portfolio in Japan and
Results from a three-year follow-up of patients administered bronchial thermoplasty found that patients experienced similar reductions in severe exacerbations, hospitalizations, and emergency room visits when compared to an earlier clinical trial.
Global downstream processing Market Size, Hit CAGR for forecast period 2016-2021
The global downstream processing market is projected to reach USD 22.03 billion by 2021 from USD 10.32 billion in 2016, at a CAGR of 16.4% from 201...
High-Throughput Process Development Instruments Market Size, By Country, 2017-2021 (USD Million)
The global high-throughput process development market is expected to reach USD 19.78 billion in 2021 from USD 9.91 billion in 2016, ...
The coalition issued subpoenas seeking information from opioid manufacturers Endo International, Janssen Pharmaceuticals, Teva Pharmaceuticals and Allergan, as well as additional subpoenas to Purdue Pharma. In addition, the group is demanding documents from distribution companies AmerisourceBergen, Cardinal Health and McKesson.
4 D Molecular Therapeutics, a leader in adeno-associated virus gene therapy vector discovery and product development, today announced $3 million in additional funding from Cystic Fibrosis Foundation Therapeutics Inc., the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to expand ongoing efforts to develop an I
Office Address: Department of Veterans Affairs; VA Sierra Pacific Network; VA Northern California HealthCare System; 5342 Dudley Blvd. Bldg 98; McClellan CA 95652-1012. Place of Performance: VA Palo Alto Healthcare System; 3801 Miranda Ave., Bldg. 100; Palo Alto, CA. Description: Department of Veterans Affairs.
Dr. Srivastava brings to Abide more than 15 years of experience with a strong background in the biopharmaceutical industry and Wall Street. Dr. Srivastava has more than 15 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street. Prior to that role, Dr. Srivastava spent over a decade on Wall Street as a Senior
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time i
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offer
Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2017, Acceleron Pharma Inc. and Celgene Corporation entered into an Amended and Restated Collaboration, License and Option Agreement that amends and restates their existing Collaboration, License and Option Agreement, dated as of February 20, 2008 and amended as of August 2, 201
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development Day in New York City today. The Company discussed clinical development plans to build therapeutic area leadership, and its long-term strategy to advance key prog
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. Sotatercept shows...
Acer Therapeutics Inc.,, a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, announced that today it completed the merger with Opexa Therapeutics, Inc., under which the stockholders of Acer become holders of 88.8% of combined
Release date- 18092017- BOTHELL, Wash. and VANCOUVER, British Columbia- Achieve Life Sciences, Inc., a clinical stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC pursuant to
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its drug candidate A-101 for the treatment of facial seborrheic keratosis lesions have been published in the journal Dermatologic Surgery. The FDA s Prescription Drug User Fee Ac
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth...
This grant builds on the previous NIH grant for the HOPE4MCI trial that established a public-private partnership among the NIA, Johns Hopkins University, and AgeneBio for the HOPE4MCI trial. "With the award of this additional funding from the NIH, we will immediately initiate the Phase 3 trial start-up with an initial cohort of clinical sites and
Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which patients with locally adv
SANTA CLARA, Calif. Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which pat
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday September 26, 2017 in New York City. To access the live webcast of t
Sept. 19 Forty-one state attorneys general, including Alabama's Steve Marshall, sent letters to several drug companies Tuesday demanding information on their role in the spread of opioid abuse. Another company, Purdue Pharma, received a "supplementary" investigative demand, according to Marshall's announcement possibly a sign that the states wa
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in September:. Cantor Fitzgerald Global Healthcare Conference Location: InterContinental New York Barclay in
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the pricing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $7.25 per share.
Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, CEO, will present at the Sidoti& Company Fall 2017 Conference at the New York Marriott Marquis in New York, New York. Alimera Sciences presentation will take place Thursday, September 28th at 9:0